Curated for Orthogate.org Members

CLINICAL OVERVIEW

Encore Medical, L.P. (a subsidiary of Enovis) has received FDA 510(k) clearance (K263086) for the AltiVate Reverse® Glenosphere with RAVN™ Technology, expanding its flagship reverse total shoulder arthroplasty (rTSA) portfolio. Designed for patients presenting with rotator cuff tear arthropathy (CTA), massive irreparable rotator cuff tears with severe pseudoparalysis, end-stage osteoarthritis with cuff compromise, and complex revision shoulder arthroplasty, the new glenosphere component builds upon Enovis's thirty-year biomechanical legacy in lateralized reverse shoulder kinematics.

The AltiVate Reverse® platform is grounded in a lateralized center of rotation (COR) design paired with an anatomic 135° humeral neck-shaft angle (NSA). In contrast to classic Grammont-style reverse shoulder prostheses—which medialize the center of rotation onto the glenoid face to maximize the deltoid moment arm at the expense of severe scapular notching, deltoid wrapping loss, and decreased rotational arc—Enovis's lateralized geometry shifts the joint center lateral to the glenoid vault. This lateralization restores tension across the remaining rotator cuff musculature (particularly the infraspinatus and teres minor), recovers active external rotation, and preserves natural deltoid contour while dramatically reducing the incidence of inferior scapular mechanical impingement (Sirveaux Grade 1–4 notching).

The newly cleared RAVN™ Technology introduces an advanced engineered modular locking and interface architecture designed to optimize glenosphere seating, maximize taper contact surface integrity, and enhance modular fixation stability on the bone-preserving AltiVate baseplate. By offering modularity in glenosphere diameter, lateral offset, and eccentric inferior overhang configurations, RAVN™ Technology enables surgeons to customize joint kinematics to patient-specific anatomy, effectively addressing severe glenoid bone erosion (Favard/Walch B2, B3, and C glenoids) and soft-tissue laxity without inducing excessive shear forces at the baseplate-bone interface.

REGULATORY & EVIDENCE PATHWAY

• Regulatory Basis: FDA 510(k) clearance K263086 granted on October 2, 2026, under 21 CFR 888.3660 (Shoulder joint metal/polymer semi-constrained cemented prosthesis; Product Code: PHX), proving substantial equivalence to the predicate AltiVate Reverse® and Reverse Shoulder Prosthesis (RSP®) lines.
• Supporting Evidence: Biomechanical fatigue characterization, dynamic range-of-motion simulation, taper disassociation pull-off testing, and shear-stress finite element analysis (FEA) performed under ASTM F1378 and ISO 14879 protocols. Results demonstrated superior modular junction stability and wear resistance across extreme cyclic loading conditions.
• Key Data Points: Long-term clinical registry data from the AltiVate Reverse® lateralized platform corroborate an inferior scapular notching rate under 10% (in sharp contrast to historical rates of 60% to 75% associated with medialized 155° Grammont designs), with patients achieving sustained mean active forward elevation exceeding 140° and active external rotation exceeding 35° out to 5-year and 10-year follow-ups.

SURGICAL WORKFLOW IMPACT

Operative implantation integrates directly with existing AltiVate Reverse® instrumentation and Enovis's 3D preoperative planning software. Surgeons prepare the glenoid face using bone-sparing reamers that preserve subchondral bone stock, followed by placement of the central peg and peripheral locking/non-locking compression screws into the scapular pillars (coracoid base and scapular spine).

The RAVN™ glenosphere connects securely to the baseplate taper with tactile and audible confirmation, streamlining final component engagement in deep, muscular shoulders or tight revision corridors where visibility is restricted. This eliminates trial-and-error alignment and reduces operative time during the critical reduction phase.

COMPETITIVE LANDSCAPE

The AltiVate Reverse® Glenosphere with RAVN™ Technology competes directly against premier rTSA systems, including Stryker / Wright Medical's Tornier Perform® Reversed and Aspyre™ systems, Zimmer Biomet's Comprehensive® Reverse, Arthrex's Univers Revers™, and DePuy Synthes' Delta XTEND™ / Inhance™ platforms.

While many competitors rely on 145° or 155° humeral onlay configurations or require allograft/metallic wedge augmentation to achieve lateralization, the Enovis system delivers bone-preserving lateralization through its modular glenosphere and 135° inlay stem design. This preserves the proximal humeral bone envelope, reduces lateral humeral offset excess that can stress the acromion, and provides a balanced mechanical environment that minimizes baseplate shear stresses and acromial stress fracture risks.

CLINICAL SIGNIFICANCE FOR ORTHOGATE MEMBERS

For shoulder and elbow specialists and reconstructive attendings, the AltiVate Reverse® Glenosphere with RAVN™ Technology delivers a refined solution to the primary failure modes of reverse arthroplasty: scapular notching, chronic instability, and loss of rotational function. The lateralized center of rotation combined with precision RAVN™ modularity restores functional external rotation without requiring latissimus dorsi tendon transfer in many patients. Furthermore, the robust taper connection and versatile sizing options provide reliable stability across challenging primary osteoarthritic shoulders and complex revision reconstructions.

Sources:

• U.S. FDA 510(k) Premarket Notification Database (K263086)
• Enovis Surgical — Shoulder Arthroplasty Solutions
• OrthoSpineNews: Arthroplasty & Extremity Reconstruction Reports